Skip to main content
Clinical Trials/NCT05878912
NCT05878912
Recruiting
Not Applicable

The Effects of Obesity and Weight Loss in Heart Failure: Imaging the Obesity Paradox Using Magnetic Resonance Imaging and Spectroscopy - Heart Failure With Preserved Ejection Fraction Substudy

University of Oxford1 site in 1 country120 target enrollmentJanuary 20, 2023

Overview

Phase
Not Applicable
Intervention
Not specified
Conditions
Heart Failure With Preserved Ejection Fraction
Sponsor
University of Oxford
Enrollment
120
Locations
1
Primary Endpoint
Left atrial volume
Status
Recruiting
Last Updated
2 years ago

Overview

Brief Summary

This study looks at the effects of weight loss in people who have heart failure with preserved ejection fraction (HFpEF) and are overweight or obese.

The main questions it aims to answer are whether weight loss in this group of people improves:

  1. The heart's shape, how well it pumps blood and how well it uses fuels
  2. The person's quality of life and how much they can exercise

Participants will attend 2 study visits, separated by 3-6 months. The intervention period takes place in between the 2 study visits.

Each study visit will involve measurements including:

  • Symptom and quality of life questionnaires
  • Body measurements such as height and weight
  • Blood tests
  • Ultrasound scans of the heart (echocardiogram)
  • Magnetic Resonance Imaging (MRI) scans of the heart
  • Exercise components during the scans
  • 6 minute walk test

Participants are randomly allocated (in other words, by lottery) to either 'diet' or 'control' groups. The control group will continue standard care.

The diet group will be enrolled in a weight loss program supervised by the study team. Participants in the diet group will replace their usual meals with meal replacement products specifically designed to deliver a low calorie diet for weight loss. The products will consist of formula soups, shakes and porridges. This diet would last 8 weeks, followed by a guided period of food reintroduction and maintenance.

Detailed Description

An interim analysis is planned at 60 recruits to review the recruitment target.

Registry
clinicaltrials.gov
Start Date
January 20, 2023
End Date
December 2026
Last Updated
2 years ago
Study Type
Interventional
Study Design
Parallel
Sex
All

Investigators

Responsible Party
Sponsor

Eligibility Criteria

Inclusion Criteria

  • Heart failure with preserved ejection fraction (HFpEF)
  • Left ventricular ejection fraction (LVEF) =/\> 50%
  • Body Mass Index (BMI) approximately =/\> 27.5 kg/m\^2

Exclusion Criteria

  • Contraindications to magnetic resonance imaging
  • NYHA class IV
  • Significant valvular, ischemic, infiltrative or other potentially confounding cardiac disease
  • Pregnancy, planned pregnancy or lactating
  • Any other conditions which may potentially compromise the safety or scientific validity of the study

Outcomes

Primary Outcomes

Left atrial volume

Time Frame: Change from baseline at 3-6 months

measured on cardiac magnetic resonance imaging

Secondary Outcomes

  • Body weight(Change from baseline at 3-6 months)
  • Six minute walk distance(Change from baseline at 3-6 months)
  • N-terminal pro brain natriuretic peptide (NT pro BNP)(Change from baseline at 3-6 months)
  • Kansas City Cardiomyopathy Questionnaire (KCCQ)(Change from baseline at 3-6 months)

Study Sites (1)

Loading locations...

Similar Trials